For the quarter ending 2025-09-30, AIMI made $26K in revenue. -$3,284K in net income. Net profit margin of -12630.77%.
| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | |
|---|---|---|---|---|
| Total revenues | 26 | 25 | 16 | |
| Production costs | 68 | 10 | 10 | |
| Research and development | 607 | 1,174 | 1,080 | |
| General and administrative | 1,798 | 1,487 | 2,545 | |
| Total costs and expenses | 2,473 | 2,671 | 3,635 | |
| Operating loss | -2,447 | -2,646 | -3,619 | |
| Gain (loss) on investments | -1 | -9 | 27 | |
| Interest and other income | 3,052 | 10 | 11 | |
| Interest expense and other finance costs | 148 | 149 | 124 | |
| Issuance cost | 433 | - | - | |
| Loss on issuance of warrants | -3,977 | 0 | - | |
| Change in fair value of warrants | -670 | - | - | |
| Net loss | -3,284 | -2,794 | -3,705 | |
| Basic loss per share | 1.57 | -3.68 | -0.05 | |
| Diluted loss per share | 1.57 | -3.68 | -0.05 | |
| Weighted average shares outstanding basic | 2,093,446 | 759,289 | 70,329,869 | |
| Weighted average shares outstanding diluted | 2,093,446 | 759,289 | 70,329,869 | |
AIM ImmunoTech Inc. (AIMI)
AIM ImmunoTech Inc. (AIMI)